New agents for the medical treatment of interstitial cystitis

Expert Opinion on Investigational Drugs

Volumn 10, Issue 3, 2001, Pages 521-546

  Theoharides, T C ^a   Sant, G R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chondroitin sulphate; Histamine 3 receptors; Hyaluronic acid; Inflammation; Interstitial cystitis; Mast cells; Pain; Quercetin

Indexed keywords

ALGONOT PLUS; AMITRIPTYLINE; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CHONDROITIN SULFATE; CROMOGLYCATE DISODIUM; CYCLOSPORIN; CYCLOSPORIN A; DESIPRAMINE; DIMETHYL SULFOXIDE; DIPYRONE; DOXEPIN; EMBREL; ETANERCEPT; GABAPENTIN; GLYCOSAMINOGLYCAN; HYDROXYZINE; HYDROXYZINE EMBONATE; IMIPRAMINE; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUPRORELIN; METHOTREXATE; MEXILETINE; MEXITIE; MONTELUKAST; PENTAZOCINE; PENTOSAN POLYSULFATE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROPIRAM FUMARATE; QUERCETIN; ROFECOXIB; SINEPUAN; SUPLATAST TOSYLATE; TAMOXIFEN; TAMOXIFEN CITRATE; TRAMADOL; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADOLESCENT; ADULT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; BLADDER BIOPSY; BLADDER DISEASE; CELL PROTECTION; CHILD; CHRONIC DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MALE; MAST CELL; MOUSE; NEUROGENIC INFLAMMATION; NEUROLYSIS; NEUROPATHY; NONHUMAN; PREVALENCE; PROSTATITIS; REVIEW; SENSORY NERVE; SENSORY STIMULATION; SIDE EFFECT; SYMPTOMATOLOGY;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROITIN; CYSTITIS, INTERSTITIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, NEUROPEPTIDE;

EID: 0035110707     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.3.521     Document Type: Review

References (234)

1. Interstitial cystitis
2. Interstitial cystitis
3. Interstitial cystitis: Early diagnosis, pathology and treatment
4. Sur la cystite interstitielle
5. Interstitial cystitis in men
6. Mast cell activation in sterile bladder and prostate inflammation
7. Bladder petechiae after cystoscopy and hydrodistension in men diagnosed with prostate pain
8. Epidemiology of interstitial cystitis
9. Epidemiology of interstitial cystitis: 2
10. Interstitial cystitis in the Netherlands: Prevalence, diagnostic criteria and therapeutic preferences
11. Epidemiology of interstitial cystitis: A population based study
12. Interstitial cystitis in children
13. Interstitial cystitis: A neuroimmunoendocrine disorder
14. The natural history of interstitial cystitis: A survey of 374 patients
15. The role of the mast cell in interstitial cystitis
16. Diagnosis of interstitial cystitis
17. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis
18. Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis
19. Clinical features and spectrum of light microscopic changes in interstitial cystitis
20. Inflammatory cell types and clinical features of interstitial cystitis
21. Inflammatory mediator profile in urine and bladder wash fluid of patients with interstitial cystitis
22. Evidence for urothelial cell activation in interstitial cystitis
23. Increased expression of intercellular adhesion molecule 1 in relation to mast cells in the bladder of interstitial cystitis patients
24. Altered expression of bladder mast cell growth factor receptor (c-kit) expression in interstitial cystitis
25. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis
26. Treatments used in women with interstitial cystitis: The interstitial cystitis data base (ICDB) study experience
27. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis - A practical approach
28. The interstitial cystitis symptom index and problem index
29. ATP, pain and a full bladder
30. 3-deficient mice
31. Opiates, mast cells and histamine release
32. Anticonvulsant drugs for management of pain: A systemic review
33. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial
34. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial
35. Interstitial cystitis and the potential role of gabapentin
36. Mexiletine in clinical practice
37. Neuropathic pain in a cancer patient responding to subcutaneously administered lignocaine
38. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache
39. Propiram. A review of its pharmacodynamic and pharmacokinetic properties and clinical use as an analgesic
40. Comparison of tramadol and acitaminophen with codeine for long-term pain management in elderlly patients
41. Use of tramadol in chronic pain
42. Central analgesic effects of desipramine, fluvoxzamine and moclobemide after single oral dosing: A study of healthy volunteers
43. Differential release of serotonin and histamine from mast cells
44. Characteristics of the inhibitory effect of tricyclic antidepressants on histamine release from rat peritoneal mast cells
45. Antidepressants, antihistamines, interstitial cystitis and cancer
46. Amitriptyline versus maprotiline in postherpetic neuralgia: A randomized, double-blind, crossover trial
47. The analgesic effect of amitriptyline on chronic facial pain
48. Use of amitriptyline in the treatment of interstitial cystitis
49. The use of amitriptyline in patients with urinary frequency and pain
50. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell
51. Desipramine relieves postherpetic neuralgia
52. Doxepin effects on chronic pain and depression: A controlled study
53. 2 receptors in human vasculature
54. Imipramine treatment of painful diabetic neuropathy
55. Endocrine allergy, I. Allergic sensitivity to endogenous hormones
56. Sex hormones and kinetics of anaphylactic histamine release
57. Estradiol augments while tamoxifen inhibits rat mast cell secretion
58. Carbachol-induced activation of bladder mast cells is augmented by estradiol - Implications for interstitial cystitis
59. Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis
60. The use of GnRH agonists in the medical therapy of endometriosis in the woman in pain
61. Debilitating 'functional' bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog
62. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis
63. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
64. Augmentation of allergic histamine release from human leukocytes by non-steroidal anti-inflammatory-analgesic agents
65. COX-2-specific inhibitors-the emergence of a new class of analgesic and anti-inflammatory drugs
66. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
67. Pyrazolone drugs in outpatients pain treatment
68. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics
69. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma
70. A randomized controlled trial comparing zileuton with theophylline in moderate asthma
71. Cyclosporine in severe interstitial cystitis
72. Anti-inflammatory effect of cyclosporin A on human skin mast cells
73. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells
74. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
75. Etanercepta: A review of its use in rheumatoid arthritis
76. Oral methotrexate in the management of refractory interstitial cystitis
77. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria
78. Alternate occurrence of allergic disease and an unusual form of interstitial cystitis
79. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis
80. Mast cells in interstitial cystitis
81. Activation of bladder mast cells in interstitial cystitis: A light and electron microscopic study
82. Subtypes of bladder mast cells in interstitial cystitis
83. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation
84. Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease
85. Increased urine histamine and methylhistamine in interstitial cystitis
86. Elevated mast cell tryptase in urine of interstitial cystitis patients
87. Experimental autoimmune cystitis: A potential murine model for ulcerative interstitial cystitis
88. Mast cells mediate the severity of experimental cystitis in mice
89. Comparative cytokine release from human monocytes, monocyte-derived immature mast cells and a human mast cell line (HMC-1)
90. Heterogeneity of human mast cells based on cytokine content
91. Production of interleukin-6 by human mast cells and basophilic cells
92. The role of mast cells and basophils in inflammation
93. Mast cell: A neuroimmunoendocrine master player
94. Human anti-IgE monoclonal antibody blocks passive sensitization of human and rhesus monkey bladder
95. Stimulated release of urine histamine in interstitial cystitis
96. Increased number of substance P positive nerve fibers in interstitial cystitis
97. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis
98. Stress-induced bladder mast cell activation: Implications for interstitial cystitis
99. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress
100. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis
101. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients
102. Nerve fibre proliferation in interstitial cystitis
103. Interstitial cystitis: Correlation with nerve fibres, mast cells and histamine
104. Interstitial cystitis: Increased sympathetic innervation and related neuropeptide synthesis
105. Nerve-mast cell interaction in normal guinea pig urinary bladder
106. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis
107. CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat
108. Glucosamine for migraine prophylaxis
109. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo
110. Two cases of interstitial cystitis complicated with migraine
111. Cimetidine in the treatment of interstitial cystitis
112. Cimetidine in treatment of interstitial cystitis
113. Cimetidine increases the plasma concentration of hydroxyzine
114. The effect of disodium cromoglycate on the release of histamine and degranulation of rat mast cells induced by compound 48/80
115. The histologic and functional characterization of enzymatically dispersed intestinal mast cells of nonhuman primates: Effects of secretagogues and anti-allergic drugs on histamine secretion
116. Mucosal mast cells. II: Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells
117. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein
118. Analgesic effects of antihistamines
119. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis
120. Objective antihistamine side effects are mitigated by evening dosing of hydroxyzine
121. 1-antagonist derived anti-allergic drugs: Relation to lipophilicity and membrane effects
122. Hydroxyzine inhibits neurogenic bladder mast cell activation
123. Hydroxyzine for interstitial cystitis
124. Hydroxyzine therapy for interstitial cystitis
125. Effect of hydroxyzine on morphine analgesia for the treatment of postoperative pain
126. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: A randomized, prospective, double-blind trial
127. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia
128. Mast cells in accessory glands of experimentally induced prostatitis in male Wistar rats
129. Expression of c-kit and kit ligand proteins in normal human tissues
130. C-kit and stem cell factor (mast cell growth factor) expression in interstitial cystitis: Clues to the pathogenesis of detrusor mastocytosis and nerve fiber proliferation
131. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues
132. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis
133. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
134. c-kit Mutation in a population of patients with mastocytosis
135. Indoline derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
136. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T
137. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer
138. Effect of flavone inhibitors of transport ATPases on histamine secretion from rat mast cells
139. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells
140. Differential effect of flavonoids on inhibition of secretion and accumulation of secretory granules in rat basophilic leukemia cells
141. Cloning and cellular localization of the rat mast cell 78kD protein phosphorylated in response to the mast cell 'stabilizer' cromolyn
142. ERM (ezrin/radixin/moesin) family: From cytoskeleton to signal transduction
143. Olive Oil
144. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells
145. Quercetin in men with category III chronic prostatitis: A preliminary prospective, double-blind, placebo-controlled trial
146. Bladder-surface glycosaminoglycans: An efficient mechanism of environmental adaptation
147. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis)
148. Increased urinary hyaluronic acid and interstitial cystitis
149. Urinary chondroitin sulfates, heparan sulfate and total sulfated glycosaminoglycans in interstitial cystitis
150. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production
151. 99mtechnetium-diethylenetriamine pentaacetic acid
152. Inhibitory effect of heparin upon histamine release by trypsin, antigen and proteose
153. Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vitro
154. Pentosanpolysulfate (Elmiron) inhibits mast cell histamine secretion and intracellular calcium ion levels: An alternative explanation of its beneficial effect in interstitial cystitis
155. Chondroitin sulfate inhibits connective tissue mast cells
156. Structure and biosynthesis of proteoglycans
157. Continuous release of secretory granule proteoglycans from a strain derived from the bone marrow of a patient with diffuse cutaneous mastocytosis
158. Stem cell factor-dependent human cord blood derived mast cells express alpha-and beta-tryptase, heparin and chondroitin sulphate
159. Glucosamine and chondroitin for treatment of osteoarthritis
160. Report flags hazards of risk assessment
161. Diet and survival of elderly Greeks: A link to the past
162. Treatment of interstitial cystitis with intravesical heparin
163. Cytochemical localization of hyaluronan in rat and human skin mast cell granules
164. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis
165. Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid
166. Human mast cells express the hyaluronic-acid-binding isoform CD44 and adhere to hyaluronic acid
167. Intravesical sodium hyaluronate inhibits rat urine mast cell mediator increase triggered by acute immobilization stress
168. A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis
169. Successful treatment of interstitial cystitis with sodium pentosanpolysulfate
170. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study
171. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: A meta-analysis
172. Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis
173. Microvascular leakage induced by substance P in rat urinary bladder: Involvement of cyclo-oxygenase metabolites of arachidonic acid
174. Kinetics of peptide-induced release of inflammatory mediators by the urinary bladder
175. The effect of acute distension on vasoactive intestinal polypeptide (VIP) neuropeptide Y (NPY) and substance P (SP) immunoreactive nerves in the female rat urinary bladder
176. Effects of bradykinin and tachykinin receptor antagonist on xylene-induced cystitis in rats
177. The effects of substance P on histamine and 5-hydroxytryptamine release in the rat
178. Release of histamine by substance P
179. Capsaicin: Actions on nociceptive C-fibres and therapeutic potential
180. Effect of capsaicin on the rabbit urinary bladder. What is the function of sensory nerves that contain substance P?
181. Impaired nociception and pain sensation in mice lacking the capsaicin receptor
182. Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract
183. Intravesical neuromodulatory drugs: Capsaicin and resiniferatoxin to treat the overactive bladder
184. Intravesical treatment of overactive bladder
185. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlled study
186. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: Long-term results for the treatment of detrusor hyperreflexia
187. 1 receptor sites, in the rat urinary bladder
188. Activity of nonpeptide tachykinin antagonists on neurokinin a induced contractions in dog urinary bladder
189. 2-induced bladder hyperactivity in normal, conscious rats: Involvement of tachykinins?
190. 1 (substance P) receptor antagonists - Why are they not analgesic in humans?
191. A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats
192. Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor
193. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels
194. Interaction of neurotensin with the substance P receptor mediating histamine release from rat mast cells and the flare in human skin
195. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
196. CRH and the immune system
197. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo
198. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects
199. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors
200. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: A link to neurogenic skin disorders
201. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheal inflammation
202. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF-and stress-related alterations of gastric and colonic motor function
203. 3) of histamine receptors
204. 3 receptors
205. 3-receptors inhibit neurogenic microvascular leakage in airways
206. 3 receptors
207. 3 receptors
208. Differential effect of histamine-3 receptor active agents on brain but not peritoneal mast cell activation
209. 3-receptor modulation in rat lung and spleen
210. 3 receptor agonists and antagonists
211. 3-receptor agonist prodrug
212. The effects of clonidine and tizanidine on responses of nociceptive neurons in nucleus ventralis posterolateralis of the cat thalamus
213. Action of clonidine on the mast cells of rats
214. Drugs used to treat spasticity
215. Modified-release formulation of tizanidine in chronic tension-type headache
216. A comparison of intrathecally administered narcotic and nonnarcotic analgesics for experimental chronic neuropathic pain
217. Nitric oxide, a novel biologic messenger
218. The dual personality of NO
219. Nitric oxide (NO) and nociceptive processing in the spinal cord
220. Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis
221. Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections
222. Improvement in interstitial cystitis symptom scores during treatment with oral L-Arginine
223. Effects of L-Arginine on symptoms and bladder nitric oxide levels on patients with interstitial cystitis
224. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis
225. Reactive oxygen species generation and histamine release by activated mast cells: Modulation by nitric oxide synthase inhibition
226. Nitric oxide inhibits numerous features of mast cell-induced inflammation
227. The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: A double-blind, prospective, placebo controlled trial
228. Intravesical bacillus calmette-guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: A prospective, randomized double-blind study
229. The influence of infections on the development and severity of allergic disorders
230. The inverse association between tuberculin responses and atopic disorder
231. Interstitial cystitis treated with intravesical doxorubicin
232. Somatostatin analogues supress the inflammatory reaction in vivo
233. Somatostatin induces histamine secretion from rat peritoneal mast cells